Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment

被引:55
|
作者
Clark, LH [1 ]
Setzer, RW [1 ]
Barton, HA [1 ]
机构
[1] US EPA, Off Res & Dev, Natl Hlth & Environm Effects Res Lab, Expt Toxicol Div, Res Triangle Pk, NC 27711 USA
关键词
model evaluation; PBPK models; pharmacokinetics; risk assessment;
D O I
10.1111/j.0272-4332.2004.00561.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Proposed applications of increasingly sophisticated biologically-based computational models, such as physiologically-based pharmacokinetic models, raise the issue of how to evaluate whether the models are adequate for proposed uses, including safety or risk assessment. A six-step process for model evaluation is described. It relies on multidisciplinary expertise to address the biological, toxicological, mathematical, statistical, and risk assessment aspects of the modeling and its application. The first step is to have a clear definition of the purpose(s) of the model in the particular assessment; this provides critical perspectives on all subsequent steps. The second step is to evaluate the biological characterization described by the model structure based on the intended uses of the model and available information on the compound being modeled or related compounds. The next two steps review the mathematical equations used to describe the biology and their implementation in an appropriate computer program. At this point, the values selected for the model parameters (i.e., model calibration) must be evaluated. Thus, the fifth step is a combination of evaluating the model parameterization and calibration against data and evaluating the uncertainty in the model outputs. The final step is to evaluate specialized analyses that were done using the model, such as modeling of population distributions of parameters leading to population estimates for model outcomes or inclusion of early pharmacodynamic events. The process also helps to define the kinds of documentation that would be needed for a model to facilitate its evaluation and implementation.
引用
收藏
页码:1697 / 1717
页数:21
相关论文
共 50 条
  • [1] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELS - EXAMPLES OF THEIR USE IN EXPOSURE AND RISK ASSESSMENT
    BLANCATO, JN
    SALEH, MA
    BIOMARKERS OF HUMAN EXPOSURE TO PESTICIDES, 1994, 542 : 264 - 283
  • [3] Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment
    Krishnan, K
    Johanson, G
    JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS, 2005, 23 (01): : 31 - 53
  • [4] Evaluation of physiologically based pharmacokinetic models for use in risk assessment
    Chiu, Weihsueh A.
    Barton, Hugh A.
    DeWoskin, Robert S.
    Schlosser, Paul
    Thompson, Chad M.
    Sonawane, Babasaheb
    Lipscomb, John C.
    Krishnan, Kannan
    JOURNAL OF APPLIED TOXICOLOGY, 2007, 27 (03) : 218 - 237
  • [5] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELS IN TOXICITY TESTING AND RISK ASSESSMENT
    Lipscomb, John C.
    Haddad, Sami
    Poet, Torka
    Krishnan, Kannan
    NEW TECHNOLOGIES FOR TOXICITY TESTING, 2012, 745 : 76 - 95
  • [6] Evaluating a physiologically-based pharmacokinetic model for use in risk assessment.
    Clark, LH
    Barton, HA
    Setzer, RW
    TOXICOLOGICAL SCIENCES, 2003, 72 : 182 - 182
  • [7] LIMITING THE UNCERTAINTY IN RISK ASSESSMENT BY THE DEVELOPMENT OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC AND PHARMACODYNAMIC MODELS
    FREDERICK, CB
    TOXICOLOGY LETTERS, 1993, 68 (1-2) : 159 - 175
  • [8] An introduction to physiologically-based pharmacokinetic models
    Upton, Richard N.
    Foster, David J. R.
    Abuhelwa, Ahmad Y.
    PEDIATRIC ANESTHESIA, 2016, 26 (11) : 1036 - 1046
  • [9] A Novel Method for Assessing Drug Degradation Product Safety Using Physiologically-Based Pharmacokinetic Models and Stochastic Risk Assessment
    Nguyen, Hoa Q.
    Stamatis, Stephen D.
    Kirsch, Lee E.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (09) : 3101 - 3119
  • [10] Have physiologically-based pharmacokinetic models delivered?
    Edginton, Andrea N.
    Joshi, Ghanashyam
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (08) : 929 - 934